Fight Pneumonia – Save a child

Gateway Health Institute is currently producing an oil based amoxicillin suspension that will remain stable at high temperatures of 40 to 50 °C for up to two years, eliminating the need for reconstitution of amoxicillin with water, enabling timely and safe treatment of Pneumonia in Children. The aim is to produce an oil based delivery method of Amoxicillin that can be orally administered to infants and small children, that does not require refrigeration, that remains chemically stable and retains therapeutic efficacy and safety at very high temperatures, such as experienced in some parts of the world, and also retains stability when exposed to direct sunlight.

Gateway Health Institute has been funded by the Bill and Melinda Gates Foundation to the tune of $100 000 dollars, however to enable us to develop and research both the 125mg/5ml and the 250mg /5ml formulations needed to treat children of all ages, we need 40 000 Euro more. Not developing and testing the 125mg/5ml formulation will be a waste of time and money – it will be advantageous to develop both formulations simultaneously, to accelerate the development of the product, to have both formulations on the market available for timely and efficient treatment of pneumonia in children across the globe